Akebia Therapeutics, Inc.
General ticker "AKBA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $609.6M (TTM average)
Akebia Therapeutics, Inc. follows the US Stock Market performance with the rate: 23.8%.
Estimated limits based on current volatility of 1.9%: low 1.49$, high 1.58$
Factors to consider:
- Total employees count: 43 as of 2014
- Top business risk factors: Insufficient funding, Labor/talent shortage/retention, Acquisition/divestiture risks, Regulatory and compliance, Supply chain disruptions
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.21$, 2.87$]
- 2025-12-31 to 2026-12-31 estimated range: [1.28$, 3.01$]
Financial Metrics affecting the AKBA estimates:
- Positive: with PPE of -5.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.37 <= 0.33
- Positive: Investing cash flow per share per price, % of -0.01 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term AKBA quotes
Long-term AKBA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $292.48MM | $194.62MM | $160.18MM |
| Operating Expenses | $373.26MM | $240.88MM | $210.65MM |
| Operating Income | $-80.78MM | $-46.26MM | $-50.47MM |
| Non-Operating Income | $-13.45MM | $-5.67MM | $-18.94MM |
| Interest Expense | $15.69MM | $6.03MM | $18.18MM |
| R&D Expense | $129.99MM | $63.08MM | $37.65MM |
| Income(Loss) | $-94.23MM | $-51.92MM | $-69.41MM |
| Profit(Loss)* | $-95.89MM | $-51.92MM | $-69.41MM |
| Stockholders Equity | $5.23MM | $-30.58MM | $-49.19MM |
| Inventory | $21.57MM | $15.69MM | $16.24MM |
| Assets | $356.05MM | $241.70MM | $220.67MM |
| Operating Cash Flow | $-73.15MM | $-23.38MM | $-40.66MM |
| Capital expenditure | $0.11MM | $0.00MM | $0.03MM |
| Investing Cash Flow | $-0.11MM | $0.00MM | $-0.03MM |
| Financing Cash Flow | $14.60MM | $-25.21MM | $49.66MM |
| Earnings Per Share** | $-0.52 | $-0.28 | $-0.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.